Who is sponsoring NCT07189403?

NCT07189403 is sponsored by Daiichi Sankyo.

What drugs are being tested in NCT07189403?

Interventions in NCT07189403: DS9051b.

What condition does NCT07189403 study?

NCT07189403 studies Advanced or Metastatic Adrenocortical Carcinoma, Metastatic Castration-resistant Prostate Cancer.

Is NCT07189403 still recruiting?

NCT07189403 is currently recruiting now. Last updated 24 February 2026.

Last reviewed 2026-02-24 · How we verify

NCT07189403

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A Study of DS9051b in Participants With Advanced or Metastatic Adrenocortical Carcinoma and Metastatic Castration-resistant Prostate Cancer

Recruiting now Phase 1 Last updated 24 February 2026

What this trial tests

Phase 1 trial testing DS9051b in Advanced or Metastatic Adrenocortical Carcinoma in 40 participants. Currently enrolling.

Timeline

4 November 2025

Primary endpoint
1 March 2028

1 March 2028

Quick facts

Lead sponsor	Daiichi Sankyo
Phase	Phase 1
Status	Recruiting now
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	40
Start date	4 November 2025
Primary completion	1 March 2028
Estimated completion	1 March 2028
Sites	6 locations across France, United Kingdom, United States

Drugs / interventions tested

DS9051b — full drug profile →

Conditions studied

Advanced or Metastatic Adrenocortical Carcinoma — all drugs for Advanced or Metastatic Adrenocortical Carcinoma →
Metastatic Castration-resistant Prostate Cancer — all drugs for Metastatic Castration-resistant Prostate Cancer →

Sponsor

Daiichi Sankyo — full company profile →

Who can join

18 and older, any sex, with Advanced or Metastatic Adrenocortical Carcinoma or Metastatic Castration-resistant Prostate Cancer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This FIH study is designed to assess the safety, tolerability, and preliminary efficacy signals of DS9051b in participants with ACC and mCRPC.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other Daiichi Sankyo trials

Trials by the same sponsor.

NCT07474649 — A Study of Bempedoic Acid/Ezetimibe/High-intensity Statin in Patients Without Cardiovascular Events · Phase 3 · not yet recruiting
NCT07206472 — A Study of Bempedoic Acid or Its Single-pill Combination Therapy With Ezetimibe in Patients With Primary Hypercholestero · active not recruiting
NCT07220616 — A First-in-Human Trial of DS3790a in Participants With Hematological Malignancies · Phase 1, PHASE2 · recruiting
NCT07268625 — Evaluating Bioequivalence of a Fixed Dose Combination Versus Individual Tablets of Bempedoic Acid / Ezetimibe, and Atorv · Phase 1 · completed
NCT07244341 — A Study of Valemetostat (DS-3201b) in Combination With Darolutamide in Metastatic Castration Resistant Prostate Cancer ( · Phase 1 · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT07189403 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Daiichi Sankyo
Last refreshed: 24 February 2026

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07189403.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing